Table 4 Treatment and outcomes of patients with MDR/RR/pre-XDR-TBTB using bedaquiline or delamanid or none.
Characteristics | Total (n = 101) | Bedaquiline (n = 32) | Delamanid (n = 25) | Non-bedaquiline or delamanid (n = 44) | χ2/Z/H | P value |
---|---|---|---|---|---|---|
Treatment | ||||||
Number of drugs administered, including bedaquiline and/or Delamanid [median (Q1, Q3)] | 6.00 (5.00, 6.00) | 6.00 (5.25, 6.00) | 6.00 (6.00, 6.00) | 5.00 (5.00, 6.00) | 18.210a | < 0.001 |
Treatment with any FQ, N (%) | 78 (77.2) | 15 (46.9) | 21 (84.0) | 42 (95.5) | 25.727 | < 0.001 |
Treatment with linezolid, N (%) | 73 (72.3) | 28 (87.5) | 25 (100) | 20 (45.5) | 29.088 | < 0.001 |
Early stopping of new drug due to adverse events before 24-week use, N (%) (n = 57) | – | 1 (3.1) | 0 (0) | – | – | – |
Interventional therapy | 10 (9.9) | 4 (12.5) | 3 (12.0) | 3 (6.8) | 1.033b | 0.695 |
Surgical resection | 5 (5.0) | 1 (3.1) | 0 (0) | 4 (9.1) | 2.390b | 0.310 |
Duration of use of bedaquiline or delamanid in weeks, median (Q1, Q3) | – | 24.00 (24.00, 24.00) | 24.00 (24.00, 26.00) | – | − 1.934a | 0.053 |
Duration of MDR/RR/Pre-XDR-TBTB treatment in weeks, median (Q1, Q3) (n = 92) | 80.00 (72.00, 96.00) | 86.00 (73.00, 104.00) | 74.00 (72.50, 78.00) | 81.50 (72.00, 97.50) | 6.484a | 0.039 |
Treatment outcomes, N (%) | ||||||
Cured | 67 (66.3) | 23 (71.9) | 19 (76.0) | 25 (56.8) | 3.270 | 0.195 |
Completed | 25 (24.8) | 8 (25.0) | 2 (8.0) | 15 (34.1) | 5.828 | 0.054 |
Failure | 0 (0) | 0 (0) | 0 (0) | 0 (0) | – | – |
Died | 0 (0) | 0 (0) | 0 (0) | 0 (0) | - | – |
Not evaluated | 3 (3.0) | 0 (0) | 0 (0) | 3 (6.8) | 2.629b | 0.334 |
Loss to follow-up | 6 (5.9) | 1 (3.1) | 4 (16.0) | 1 (2.3) | 4.769b | 0.067 |
Treatment success | 92 (91.1) | 31 (96.9) | 21 (84.0) | 40 (90.9) | 2.768b | 0.210 |
Culture outcomes, N (%) (n = 85) | n = 85 | n = 31 | n = 18 | n = 36 | ||
Culture conversion, N (%) (n = 85) | 83(97.6) | 31 (100) | 18 (100) | 34 (94.4) | 1.875b | 0.506 |
Cultrue conversion after 2 months of treatment, N (%) (n = 85) | 57 (67.1) | 28 (90.3) | 14 (77.8) | 15 (41.7) | 17.247 | < 0.001 |
Cultrue conversion at 6 months of treatment, N (%) (n = 85) | 74 (87.1) | 30 (96.8) | 18 (100) | 26 (72.2) | 9.001b | < 0.001 |
Median time to culture conversion, weeks (95% CI)c | 4.00 (2.00, 12.00) | 2.00 (2.00, 8.00) | 2.00 (2.00, 8.00) | 12.00 (7.00, 24.00) | 26.492a | < 0.001 |
Outcomes of chest CT imaging features | ||||||
Outcomes of atelectasis at the end of treatment in CT images, N (%) (n = 36)d | n = 36 | n = 5 | n = 11 | n = 20 | 4.184a | 0.123 |
Constant | 6 (16.7) | 2 (40.0) | 3 (27.3) | 1 (5.0) | ||
Partially reexpansion | 11 (30.6) | 2 (40.0) | 2 (18.2) | 7 (35.0) | ||
Completely reexpansion | 14 (38.9) | 1 (20.0) | 5 (45.5) | 8 (40.0) | ||
Deterioration | 2 (5.6) | 0 (0) | 1 (9.1) | 1 (5.0) | ||
Receiving surgery | 3 (8.3) | 0 (0) | 0 (0) | 3 (15.0) | ||
Outcomes of stenosis at the end of treatment in CT images, N (%) (n = 60)e | n = 60 | n = 19 | n = 14 | n = 27 | 13.903a | 0.001 |
Constant | 24 (40.0) | 14 (73.7) | 4 (28.6) | 6 (22.2) | ||
Improved | 30 (50) | 5 (26.3) | 9 (64.3) | 16 (59.3) | ||
Deterioration | 4 (6.7) | 0 (0) | 1 (7.1) | 3 (11.1) | ||
Surgery | 2 (3.3) | 0 (0) | 0 (0) | 2 (7.4) | ||
Outcomes of pulmonary cavities at the end of treatment, N (%) (n = 54)f | n = 54 | n = 18 | n = 11 | n = 25 | 0.982a | 0.612 |
Constant | 3 (5.6) | 1 (5.6) | 0 (0) | 2 (8.0) | ||
Cavity reduction | 14 (25.9) | 6 (33.3) | 3 (27.3) | 5 (20.0) | ||
Cavity closure | 32 (59.3) | 10 (55.6) | 8 (72.7) | 14 (56.0) | ||
Cavity cleaning | 2 (3.7) | 0 (0) | 0 (0) | 2 (8.0) | ||
Deterioration | 1 (1.9) | 1 (5.6) | 0 (0) | 0 (0) | ||
Surgery | 2 (3.7) | 0 (0) | 0 (0) | 2 (8.0) |